Taysha Gene Therapies, Inc. (TSHA) bonds
TSHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$3.99−0.01 (-0.25%)
Close on Nov 18, 2026Market cap $1.30BP/E –Yield –
Debt
Borrowings on the balance sheet, Jun 30, 2026
Total debt
$49.26M
Long-term debt
Net debt
-$406.15M
After $455.41M of cash
Implied interest rate
0.13%
FY2025 interest ÷ average debt
Interest coverage
-1753.9×
FY2025 operating income ÷ interest
Total debt by fiscal year
Long-term plus current debt, USD
Notes and loans outstanding
As tagged in Taysha Gene Therapies's 10-Q for the period ended Jun 30, 2026
Taysha Gene Therapies's filings do not break debt down by note
The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed.
Credit facilities
Revolving credit lines and other committed borrowing capacity
| Facility | Size | Drawn | Expires |
|---|---|---|---|
| 2023 Trinity Term Loan Agreement | $40.00M | – | Nov 13, 2028 |
| 2025 Trinity Term Loan Agreement | $50.00M | $50.00M | Aug 1, 2030 |
See a number that looks wrong?